Novartis Reports real-world evidence Data for Avacopan in Transthyretin cardiomyopathy

Novartis today announced real-world evidence results for Avacopan in patients with Transthyretin cardiomyopathy. The study demonstrated that Avacopan reduces biomarker levels substantially compared to standard of care or placebo. These results provide important insights into the treatment of Transthyretin cardiomyopathy and support the continued development of Avacopan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Avacopan was consistent with previous observations, with no new safety signals identified.